Name: May 22nd Closing Market Review: "Do I still not have Samjeon-Nix?" No matter how much I search, there's no stock cheaper than Samsung Electronics right now | Hong Seon-ae, Lee Kwon-hee, Kim Jang-yeol [Closing Bell Live]
Uploaded: 2026-05-21T08:35:57+00:00
Duration: 4339 s

Speakers

Kim Jang-yeol — Reporter, The Bell

Lee Kwon-hee — CEO, Economist

Summary

The May 22nd Closing Bell Live covered a massive KOSPI rally driven by Samsung Electronics' labor agreement, Trump's ceasefire comments, and Nvidia's earnings. Panelists Kim Jang-yeol and Lee Kwon-hee argued Samsung Electronics remains the cheapest stock in the market and recommended buying on dips. They also highlighted opportunities in semiconductor supply chain stocks (substrate, capacitors, transformers), robotics due to labor automation, and biotech plays like Hanall Biopharma and Alteogen.

KOSPI surged 8% on May 22, recovering 7,800 level.
Key catalysts: Samsung labor deal, Trump ceasefire mention, Nvidia quarterly results.
Samsung Electronics called the cheapest stock in KOSPI; Nomura target 590,000 won.
Semiconductor supply chain stocks (substrate, PCB, capacitors) favored on AI CPU volume growth.
Transformer stocks rebounded after 30% correction; buy-on-dip opportunity.
Robotics theme tied to Samsung union driving automation adoption.
Hanall Biopharma jumped on positive rheumatoid arthritis trial results with J&J.
Alteogen expected to benefit from SC formulation of Keytruda; patience advised.

Trade Ideas

Kim Jang-yeol Reporter, The Bell 2:59

Robotics benefits from labor union.

The Samsung Electronics labor union agreement signals that automation and robotics adoption will accelerate in Korea as companies seek to reduce labor dependency. This structural theme benefits robotics-related stocks such as Rainbow Robotics and Robotis, which are already showing strong momentum.

Kim Jang-yeol Reporter, The Bell 26:22

Hyosung Heavy transformer correction rebound.

Transformer stocks (e.g., Hyosung Heavy Industries) peaked on May 7 after a sharp run-up, then corrected over 30%. This correction created a margin of safety (30%+ downside from highs). The rebound began today, and late buyers from yesterday or today can profit as the sector recovers, though target prices should not be chased.

Lee Kwon-hee CEO, Economist 33:26

Substrate stocks benefit from CPU volume.

Nvidia's Vera and Grace GPU architectures require significantly more CPU substrates, with volume expected to triple. This directly benefits substrate and PCB companies such as Simtech, TLB, and Korea Circuit, whose products are in short supply. These stocks should see sustained demand growth from the AI infrastructure buildout.

Lee Kwon-hee CEO, Economist 35:19

Samsung Electro-Mechanics silicon capacitor contract.

Samsung Electro-Mechanics has secured a silicon capacitor contract with Nvidia for high-performance AI chips. This is a high-margin product (minimum 20% margin), generating incremental revenue of approximately 1.6 trillion won annually. With target prices reaching 1.7 million won, the stock still has significant upside before fair value, and the contract could expand to other customers.

Lee Kwon-hee CEO, Economist 38:30

Daeduck Electronics FCBGA technology leader.

Daeduck Electronics is the technology leader among small/medium PCB and substrate companies. It is the only Korean firm producing FCBGA substrates, and also makes high-layer MLB and PCBs. With capacity expansion (10 new lines) and strong demand due to supply shortages, the stock still has room to run toward target prices despite a recent earnings miss.

Lee Kwon-hee CEO, Economist 41:14

Hanall Biopharma positive clinical results.

Hanall Biopharma reported positive clinical trial results for its rheumatoid arthritis treatment (HL036) in collaboration with Janssen (J&J subsidiary). The autoimmune drug candidate targets a large market, and the success triggered an immediate limit-up. Further upside is expected as regulatory milestones approach.

Lee Kwon-hee CEO, Economist 42:35

Alteogen SC formulation potential catalyst.

Alteogen's subcutaneous (SC) formulation of Keytruda (pembrolizumab) is gaining traction. A patient survey showed 65% preference for SC injection over IV infusion. As global approvals expand and SC penetration increases, Alteogen's royalties and revenue should grow. Near-term patience is needed as the stock digests earlier gains, but the setup is positive.

Kim Jang-yeol Reporter, The Bell 55:18

Samsung Electronics is cheapest KOSPI stock.

Samsung Electronics is the cheapest stock in the KOSPI by valuation (P/B, P/E) despite recent price increase. The company's strong ROE, structural earnings power, and lowering discount rate support valuation expansion. Nomura's 590,000 won target is achievable, and even a conservative safety margin (0.7-0.8x target) implies upside from current levels. Investors should buy on dips with a long-term horizon.

May 22nd Closing Market Review: "Do I still not have Samjeon-Nix?" No matter how much I search, there's no stock cheaper than Samsung Electronics right now | Hong Seon-ae, Lee Kwon-hee, Kim Jang-yeol [Closing Bell Live]

Summary

Trade Ideas

Up Next